Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is avail...
Saved in:
| Published in | PloS one Vol. 14; no. 12; p. e0226077 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
13.12.2019
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0226077 |
Cover
| Abstract | Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model.
Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA).
The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90.
Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients. |
|---|---|
| AbstractList | Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model. Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA). The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R.sup.2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90. Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients. Introduction Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model. Methods Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA). Results The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90. Conclusions Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients. Introduction Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model. Methods Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA). Results The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R.sup.2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90. Conclusions Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients. Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model. Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA). The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90. Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients. Introduction Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model. Methods Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA). Results The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90. Conclusions Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients. Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model.INTRODUCTIONInnovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model.Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA).METHODSData was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA).The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90.RESULTSThe beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90.Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients.CONCLUSIONSSelected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients. |
| Audience | Academic |
| Author | Stuiver, Martijn M. van Overveld, Lydia F. J. van den Brekel, Michiel W. M. van Harten, Wim H. Beck, Ann-Jean C. C. Takes, Robert P. Kieffer, Jacobien M. Retèl, Valesca P. |
| AuthorAffiliation | University of Colorado Denver, UNITED STATES 4 Radboud University Medical Center, Radboud Institute for Health Sciences, Scientific Center for Quality of Healthcare, Nijmegen, the Netherlands 3 Department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands 7 Department of Oral and Maxillofacial Surgery, Amsterdam University Medical Center, Amsterdam, the Netherlands 5 Department of Otolaryngology and Head and Neck surgery, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands 8 Department of Clinical Epidemiology Biostatistics and Bioinformatics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands 2 Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands 1 Department of Head and Neck Oncology and Surgery, the Netherlands Cancer Institute, Amsterdam, the Netherlands 6 Institute of Phonetic Sciences, University of Amst |
| AuthorAffiliation_xml | – name: 2 Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands – name: 7 Department of Oral and Maxillofacial Surgery, Amsterdam University Medical Center, Amsterdam, the Netherlands – name: 6 Institute of Phonetic Sciences, University of Amsterdam, Amsterdam, the Netherlands – name: University of Colorado Denver, UNITED STATES – name: 4 Radboud University Medical Center, Radboud Institute for Health Sciences, Scientific Center for Quality of Healthcare, Nijmegen, the Netherlands – name: 5 Department of Otolaryngology and Head and Neck surgery, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands – name: 8 Department of Clinical Epidemiology Biostatistics and Bioinformatics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands – name: 1 Department of Head and Neck Oncology and Surgery, the Netherlands Cancer Institute, Amsterdam, the Netherlands – name: 3 Department of Health Technology and Services Research, University of Twente, Enschede, the Netherlands |
| Author_xml | – sequence: 1 givenname: Ann-Jean C. C. orcidid: 0000-0002-1301-9603 surname: Beck fullname: Beck, Ann-Jean C. C. – sequence: 2 givenname: Jacobien M. surname: Kieffer fullname: Kieffer, Jacobien M. – sequence: 3 givenname: Valesca P. surname: Retèl fullname: Retèl, Valesca P. – sequence: 4 givenname: Lydia F. J. surname: van Overveld fullname: van Overveld, Lydia F. J. – sequence: 5 givenname: Robert P. surname: Takes fullname: Takes, Robert P. – sequence: 6 givenname: Michiel W. M. orcidid: 0000-0002-6338-6743 surname: van den Brekel fullname: van den Brekel, Michiel W. M. – sequence: 7 givenname: Wim H. surname: van Harten fullname: van Harten, Wim H. – sequence: 8 givenname: Martijn M. surname: Stuiver fullname: Stuiver, Martijn M. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31834892$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1v0zAYhSM0xD7gHyCwhDSNixQ7TpxkF0xTGWxSoeoY3FpvHLv1SO0QOwj49bhritppQsgXsZznHNvH5zDaM9bIKHpO8IjQnLy5tX1noBm1YXmEk4ThPH8UHZCSJjFLMN3bmu9Hh87dYpzRgrEn0T4lBU2LMjmIfn-EttVmjvxCoovp9c0YzSazeEwxAlPfzS-PP9EMebtGZnH2DinboYWE-o4xUnxDAoyQ3Skag0G1dhKcjF0rhVZaoN7rRnstHaokspUHbWR99jR6rKBx8tnwPYq-vL-4GV_Gk-mHq_H5JBYsYT5OSwwKA5SSFkW4o6JlnQLBBWVCUEISSGuRiQJSULnIWJpnLKtURaVSKatqehS9XPu2jXV8iM3xhCZZiXFa5oF4OxB9tZS1kMZ30PC200vofnELmu_-MXrB5_YHZyXBrCDB4GQw6Oz3XjrPl9oJ2TRgpO1Xe1GSZCH7IqCv7qEPn2ig5tBIro2yYV-xMuXnDBdZSUrCAjV6gAqjlkstQi-UDus7gtc7gsB4-dPPoXeOX32-_n92-nWXPd5iQzMav3C2Ce9ujdsFX2wn_TfiTSEDcLoGRGed66TiQntY-YSr6YYTzFft34TGV-3nQ_uDOL0n3vj_U_YHJB8FTg |
| CitedBy_id | crossref_primary_10_1177_0272989X231188134 crossref_primary_10_1186_s12955_020_01629_0 crossref_primary_10_1186_s12962_021_00291_7 crossref_primary_10_3390_cancers13215529 crossref_primary_10_1016_j_jtcme_2022_03_004 crossref_primary_10_1002_hed_26442 crossref_primary_10_1186_s43163_024_00642_0 crossref_primary_10_3389_fpubh_2023_1076879 crossref_primary_10_3390_biomedicines11061696 crossref_primary_10_1002_lary_28954 crossref_primary_10_1002_cncr_33936 crossref_primary_10_3390_cancers16122256 crossref_primary_10_3390_cancers14092135 crossref_primary_10_1080_09638288_2021_1966677 crossref_primary_10_1007_s11136_023_03540_9 crossref_primary_10_1007_s11136_023_03554_3 crossref_primary_10_3390_cancers14194630 |
| Cites_doi | 10.1016/j.jval.2011.12.014 10.1214/aos/1176344136 10.1007/s00066-015-0824-4 10.1111/j.1524-4733.2008.00405.x 10.1016/j.ejca.2016.08.005 10.1001/archotol.126.4.459 10.1186/1477-7525-12-35 10.1016/j.jval.2010.12.009 10.1016/j.jval.2016.11.006 10.1016/S0140-6736(86)90837-8 10.1186/s12955-014-0163-7 10.1177/0272989X06290496 10.1037/1082-989X.11.1.54 10.1586/14737167.2013.850420 10.1007/s10198-010-0233-7 10.1186/1477-7525-10-151 10.2307/1907382 10.1007/1-4020-5511-0 10.1111/coa.12724 10.2307/271063 10.1093/jnci/85.5.365 10.1016/j.ejca.2017.03.006 10.1007/s11136-011-0037-y 10.5114/aoms.2013.34317 10.1186/1477-7525-5-70 10.1007/s11136-012-0213-8 10.1111/j.1524-4733.2009.00569.x |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 Public Library of Science 2019 Beck et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2019 Beck et al 2019 Beck et al |
| Copyright_xml | – notice: COPYRIGHT 2019 Public Library of Science – notice: 2019 Beck et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2019 Beck et al 2019 Beck et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM |
| DOI | 10.1371/journal.pone.0226077 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Opposing Viewpoints In Context (Gale) Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (subscription) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Agricultural Science Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Economics |
| DocumentTitleAlternate | Mapping the EORTC QLQ-C30 and QLQ-H&N35 to EQ-5D in head and neck cancer |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2325900497 PMC6910681 A608591916 31834892 10_1371_journal_pone_0226077 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom--UK England Netherlands |
| GeographicLocations_xml | – name: Netherlands – name: England – name: United Kingdom--UK |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. ADRAZ BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c626t-490af0aa9e388077f39d4a10836cc3112a4dc5c8a4af7c5647565bfb3eff46bd3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Feb 05 03:13:57 EST 2023 Thu Aug 21 14:31:22 EDT 2025 Fri Sep 05 08:52:29 EDT 2025 Fri Jul 25 10:29:25 EDT 2025 Tue Jun 17 21:09:10 EDT 2025 Tue Jun 10 20:57:00 EDT 2025 Fri Jun 27 04:05:46 EDT 2025 Fri Jun 27 04:48:18 EDT 2025 Thu May 22 21:15:32 EDT 2025 Wed Feb 19 02:30:55 EST 2025 Thu Apr 24 23:03:34 EDT 2025 Tue Jul 01 00:54:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c626t-490af0aa9e388077f39d4a10836cc3112a4dc5c8a4af7c5647565bfb3eff46bd3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Competing Interests: The authors have read the journal's policy and the authors of this manuscript have the following competing interests: AB and MS are supported by a non-restricted research grant from ATOS Medical Sweden contributing to the existing infrastructure for health-related quality of life research of the department of Head and Neck Oncology and Surgery. ATOS Medical Sweden had no involvement in the development and conduction of the study. |
| ORCID | 0000-0002-1301-9603 0000-0002-6338-6743 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0226077 |
| PMID | 31834892 |
| PQID | 2325900497 |
| PQPubID | 1436336 |
| PageCount | e0226077 |
| ParticipantIDs | plos_journals_2325900497 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6910681 proquest_miscellaneous_2331258668 proquest_journals_2325900497 gale_infotracmisc_A608591916 gale_infotracacademiconefile_A608591916 gale_incontextgauss_ISR_A608591916 gale_incontextgauss_IOV_A608591916 gale_healthsolutions_A608591916 pubmed_primary_31834892 crossref_citationtrail_10_1371_journal_pone_0226077 crossref_primary_10_1371_journal_pone_0226077 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-12-13 |
| PublicationDateYYYYMMDD | 2019-12-13 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2019 |
| Publisher | Public Library of Science |
| Publisher_xml | – name: Public Library of Science |
| References | L McKenzie (pone.0226077.ref008) 2009; 12 LF van Overveld (pone.0226077.ref014) 2017; 42 AS Pickard (pone.0226077.ref035) 2007; 5 AC Sherman (pone.0226077.ref003) 2000; 126 A Kanatas (pone.0226077.ref033) 2010; 48 J Tobin (pone.0226077.ref011) 1958 R Crott (pone.0226077.ref007) 2010; 11 JM Bland (pone.0226077.ref022) 1986; 327 NK Aaronson (pone.0226077.ref002) 1993; 85 A Raftery (pone.0226077.ref020) 1995; 25 H McTaggart-Cowan (pone.0226077.ref036) 2013; 13 WL Tsai (pone.0226077.ref025) 2013; 22 PW Sullivan (pone.0226077.ref009) 2006; 26 MH Alava (pone.0226077.ref010) 2012; 15 L Longworth (pone.0226077.ref013) 2014 A Bozec (pone.0226077.ref029) 2016; 67 AJ Wailoo (pone.0226077.ref006) 2017; 20 G Schwarz (pone.0226077.ref021) 1978; 6 LH Sobin (pone.0226077.ref024) 2011 I Khan (pone.0226077.ref034) 2014; 12 M Hunger (pone.0226077.ref012) 2011; 14 N Kontodimopoulos (pone.0226077.ref030) 2009; 12 S Tribius (pone.0226077.ref027) 2015; 191 S Hoxbroe Michaelsen (pone.0226077.ref028) 2017; 78 SH Kim (pone.0226077.ref031) 2012; 10 EW Steyerberg (pone.0226077.ref023) 2008 PM Fayers (pone.0226077.ref015) 2001 Springer (pone.0226077.ref019) 1998 F Cribari-Neto (pone.0226077.ref017) 2010; 34 S Rogers (pone.0226077.ref032) 2006; 35 M Smithson (pone.0226077.ref018) 2006; 11 J Cohen (pone.0226077.ref016) 1977 I Proskorovsky (pone.0226077.ref004) 2014; 12 M Zmijewska-Tomczak (pone.0226077.ref026) 2014; 10 E-j Kim (pone.0226077.ref005) 2012; 21 A Szende (pone.0226077.ref001) 2007 |
| References_xml | – start-page: 199 volume-title: Selected papers of hirotugu akaike year: 1998 ident: pone.0226077.ref019 – volume: 15 start-page: 550 issue: 3 year: 2012 ident: pone.0226077.ref010 article-title: Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values publication-title: Value in Health doi: 10.1016/j.jval.2011.12.014 – volume: 6 start-page: 461 issue: 2 year: 1978 ident: pone.0226077.ref021 article-title: Estimating the dimension of a model publication-title: The annals of statistics doi: 10.1214/aos/1176344136 – volume: 191 start-page: 501 issue: 6 year: 2015 ident: pone.0226077.ref027 article-title: Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: Results of a prospective study publication-title: Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft doi: 10.1007/s00066-015-0824-4 – volume: 12 start-page: 167 issue: 1 year: 2009 ident: pone.0226077.ref008 article-title: Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data publication-title: Value in Health doi: 10.1111/j.1524-4733.2008.00405.x – volume: 67 start-page: 73 year: 2016 ident: pone.0226077.ref029 article-title: Evaluation of the information given to patients undergoing head and neck cancer surgery using the EORTC QLQ-INFO25 questionnaire: A prospective multicentric study publication-title: European journal of cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2016.08.005 – volume: 126 start-page: 459 issue: 4 year: 2000 ident: pone.0226077.ref003 article-title: Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35) publication-title: Archives of otolaryngology—head & neck surgery doi: 10.1001/archotol.126.4.459 – volume: 12 start-page: 35 issue: 1 year: 2014 ident: pone.0226077.ref004 article-title: Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma publication-title: Health and quality of life outcomes doi: 10.1186/1477-7525-12-35 – volume: 14 start-page: 759 issue: 5 year: 2011 ident: pone.0226077.ref012 article-title: Analysis of SF-6D index data: is beta regression appropriate? publication-title: Value in Health doi: 10.1016/j.jval.2010.12.009 – volume: 20 start-page: 18 issue: 1 year: 2017 ident: pone.0226077.ref006 article-title: Mapping to Estimate Health-State Utility from Non–Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report publication-title: Value in Health doi: 10.1016/j.jval.2016.11.006 – volume: 327 start-page: 307 issue: 8476 year: 1986 ident: pone.0226077.ref022 article-title: Statistical methods for assessing agreement between two methods of clinical measurement publication-title: The lancet doi: 10.1016/S0140-6736(86)90837-8 – volume: 12 start-page: 163 issue: 1 year: 2014 ident: pone.0226077.ref034 article-title: A non-linear beta-binomial regression model for mapping EORTC QLQ-C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches publication-title: Health and quality of life outcomes doi: 10.1186/s12955-014-0163-7 – volume: 26 start-page: 401 issue: 4 year: 2006 ident: pone.0226077.ref009 article-title: Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample publication-title: Medical Decision Making doi: 10.1177/0272989X06290496 – volume: 11 start-page: 54 issue: 1 year: 2006 ident: pone.0226077.ref018 article-title: A better lemon squeezer? Maximum-likelihood regression with beta-distributed dependent variables publication-title: Psychological methods doi: 10.1037/1082-989X.11.1.54 – volume: 34 start-page: 24 issue: 2 year: 2010 ident: pone.0226077.ref017 publication-title: Beta Regression in R. 2010 – volume-title: TNM classification of malignant tumours year: 2011 ident: pone.0226077.ref024 – volume: 13 start-page: 753 issue: 6 year: 2013 ident: pone.0226077.ref036 article-title: Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature publication-title: Expert review of pharmacoeconomics & outcomes research doi: 10.1586/14737167.2013.850420 – volume: 11 start-page: 427 issue: 4 year: 2010 ident: pone.0226077.ref007 article-title: Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences publication-title: The European journal of health economics doi: 10.1007/s10198-010-0233-7 – volume: 10 start-page: 151 issue: 1 year: 2012 ident: pone.0226077.ref031 article-title: Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients publication-title: Health and quality of life outcomes doi: 10.1186/1477-7525-10-151 – start-page: 24 year: 1958 ident: pone.0226077.ref011 article-title: Estimation of relationships for limited dependent variables publication-title: Econometrica: journal of the Econometric Society doi: 10.2307/1907382 – volume-title: Statistical power analysis for the behavioral sciences year: 1977 ident: pone.0226077.ref016 – volume-title: EQ-5D value sets: inventory, comparative review and user guide year: 2007 ident: pone.0226077.ref001 doi: 10.1007/1-4020-5511-0 – volume: 42 start-page: 322 issue: 2 year: 2017 ident: pone.0226077.ref014 article-title: Quality indicators of integrated care for patients with head and neck cancer publication-title: Clinical otolaryngology: official journal of ENT-UK; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery doi: 10.1111/coa.12724 – volume: 25 start-page: 111 year: 1995 ident: pone.0226077.ref020 article-title: bayesian model selection in social research publication-title: Sociological Methodology doi: 10.2307/271063 – year: 2014 ident: pone.0226077.ref013 publication-title: Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: systematic review, statistical modelling and survey – volume: 85 start-page: 365 issue: 5 year: 1993 ident: pone.0226077.ref002 article-title: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology publication-title: Journal of the National Cancer Institute doi: 10.1093/jnci/85.5.365 – year: 2001 ident: pone.0226077.ref015 publication-title: EORTC QLQ-C30 scoring manual – volume: 78 start-page: 91 year: 2017 ident: pone.0226077.ref028 article-title: Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients publication-title: European journal of cancer (Oxford, England: 1990) doi: 10.1016/j.ejca.2017.03.006 – volume: 48 start-page: 579 issue: 8 year: 2010 ident: pone.0226077.ref033 publication-title: A systematic review of patient self-completed questionnaires suitable for oral and maxillofacial surgery – volume: 21 start-page: 1193 issue: 7 year: 2012 ident: pone.0226077.ref005 article-title: Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients publication-title: Quality of Life Research doi: 10.1007/s11136-011-0037-y – volume: 10 start-page: 1153 issue: 6 year: 2014 ident: pone.0226077.ref026 article-title: Factors influencing quality of life in patients during radiotherapy for head and neck cancer publication-title: Archives of medical science: AMS doi: 10.5114/aoms.2013.34317 – volume-title: Clinical prediction models: a practical approach to development, validation, and updating year: 2008 ident: pone.0226077.ref023 – volume: 35 start-page: 913 issue: 10 year: 2006 ident: pone.0226077.ref032 publication-title: Patients’ perceived health status following primary surgery for oral and oropharyngeal cancer – volume: 5 start-page: 70 issue: 1 year: 2007 ident: pone.0226077.ref035 article-title: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer publication-title: Health and quality of life outcomes doi: 10.1186/1477-7525-5-70 – volume: 22 start-page: 715 issue: 4 year: 2013 ident: pone.0226077.ref025 article-title: Prognostic value of quality of life measured after treatment on subsequent survival in patients with nasopharyngeal carcinoma publication-title: Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation doi: 10.1007/s11136-012-0213-8 – volume: 12 start-page: 1151 issue: 8 year: 2009 ident: pone.0226077.ref030 article-title: Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments publication-title: Value in Health doi: 10.1111/j.1524-4733.2009.00569.x |
| SSID | ssj0053866 |
| Score | 2.4243321 |
| Snippet | Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients.... Introduction Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access... Introduction Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access... |
| SourceID | plos pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0226077 |
| SubjectTerms | Adult Analysis Antineoplastic Agents - therapeutic use Bayes Theorem Bayesian analysis Biology and Life Sciences Cancer Cancer treatment Care and treatment Cost analysis Cost benefit analysis Economics Emotions Epidemiology Female Global health Head & neck cancer Head and neck cancer Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - pathology Head and Neck Neoplasms - psychology Health sciences Health Status Hospitals Humans Innovations Least-Squares Analysis Male Mapping Maxillofacial surgery Medical equipment Medicine and Health Sciences Middle Aged Models, Statistical Oncology Pain Patients Performance evaluation Quality of Life Questionnaires Radiation therapy Regression analysis Regression models Research and Analysis Methods Shrinkage Social Sciences Statistical analysis Surgery Systematic review Technological change Utilities World health |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdG9wAviI2PFQYYhPh48NbUjt0goWmUTgWxju4D7S1yHHsgqqQs7Qt_PXeOUwiagLdK_qVK7Lvzz8nd7wh5phLrEi36mFbBGfDbiCX9uM8iabjXF7deUuhwIsdn4sN5fL5GJk0tDKZVNjHRB-q8NPiOfBd2fmxwKRK1N__OsGsUfl1tWmjo0Fohf-Mlxq6RdQjJca9D1t-OJp-Om9gM3i1lKKDjKtoN67UzLwu7A7uZ7CnV2qBCmO7MZ2V1FQf9M5Xyt73p4Ba5GUgl3a-tYIOs2WKTXG9qjqtNshFcuKIvg870q9vkx6FGcYYLChyQjo6OT4d0-nHKhrxHdZH73-PnEx7TRVlDpix-R4HkUgjguccU1nyjBg3n8jUd6oKG7z0MCzgxCYmCXc-8aCvNLC0zfBFh87075OxgdDocs9CKgRk48SyYSHra9bROLIrHKOV4kgsdobS1MRw4mxa5ic1AC-2UiaVQQBQzl3HrnJBZzu-STgGTvEWodbkRwkWRNnAUi3SW2aSvlDLORQb4VJfwZv5TE3TKsV3GLPUf3xScV-pZTXHV0rBqXcJWV81rnY5_4B_j0qZ1tenKzdN9iYpvcIiVXfLUI1Ako8AsnAu9rKr0_dHn_wCdHLdALwLIlfAkRofKB7gdFN9qIbdbSHB10xreQkNsHqhKfzkFXNkY59XDT1bD-KeYWVfYcokYDp4CbjHoknu1La8mEOO9GCT9LlEtK18BUJu8PVJ8_eI1yiXQUDmI7v_9th6QG0BAfT-OiG-TzuJyaR8CyVtkj4Ln_gRtEU7z priority: 102 providerName: ProQuest |
| Title | Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31834892 https://www.proquest.com/docview/2325900497 https://www.proquest.com/docview/2331258668 https://pubmed.ncbi.nlm.nih.gov/PMC6910681 http://dx.doi.org/10.1371/journal.pone.0226077 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLW2TkJ7QYyvFUoxCPHxkKppnLhBQtMoLQWxjpYV9S1yHHsgqqQ0rQT8eu51nIigIhAvUSQfR7F9b3wcX59LyCMeKh0K1sOwCs8Bfus6Yc_vOW4gPaMvroyk0NkkGM_Z24W_2CNlzlbbgfnOpR3mk5qvl51vX7-fgMO_MFkbuFtW6qyyVHVgTgq6nO-TA7NjhMF8rNpXAO8OAnuA7k81D8kVtHPWD3u1ucp-sRurZZbvoqO_R1X-Mk2NrpGrll_S08IgjsieSq-TI-vBOX1qZaaf3SA_zgRqM1xSoIB0eD67GNDpu6kz8LpUpIm5Hz-eeD7dZAVk6vivKHBcCt_vxGBSJb9QiXazfk4HIqV2u8fB85sYg0TBrJdGs5XGimYx_odQyclNMh8NLwZjx2ZicCQseDYOC7tCd4UIFWrHcK69MGHCRWVrKT2gbIIl0pd9wYTm0g8YB54Y69hTWrMgTrxbpJFCHx8TqnQiGdOuKySsxFwRxyrscc6l1q4EOtUkXtnnkbQy5ZgtYxmZvTcOy5WiJyMctMgOWpM4Va1VIdPxF_x9HM6oOGxaeXl0GqDgG6xhgyZ5aBCokZFiEM6l2OZ59Ob84z-APsxqoCcWpDNoiRT24AO8Dmpv1ZCtGhI8XdaKj9H4ygblEbBhTPrKQmhPqzTI3cUPqmJ8KAbWpSrbIsYDigte0W-S24X9Vh1YukGT8JplVwCUJq-XpJ8_GYnyAFho0Hfv_HfNu-QQqKnJ1OF6LdLYrLfqHtC_Tdwm-3zB4dofuHgdvW6Tg5fDyftZ2_xQaRuP_wnlPlz6 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdG9zBeEBsfKwxmEJ8P2ZrYiRukaRpdp5a1HS0d2ltwHHsgqqQsrRD8cfxt3KVOIWgCXvYWyZcv-3z3s333O0KeiFCbUHIPwyqYA_jWdULP9xw3UKzgF9cFpVB_EHRO-Zsz_2yF_ChzYTCssrSJhaFOMoV75Lvg-bHAJQ_F_vSLg1Wj8HS1LKEhbWmFZK-gGLOJHcf621dYwuV73UMY76eed9QetzqOrTLgKADzM4eHDWkaUoYaeVGEMCxMuHSRtVkpBnBE8kT5qim5NEL5AReAgWITM20MD-KEwXOvkVWOGyg1svq6PXg7Kn0BWJMgsAl7TLi7Vj92plmqd8B7BvC-ikO0bqE2nWT5ZZj3z9DN33zh0U1yw4JYerDQunWyotMNslbmOOcbZN2ajJy-sLzWL2-R732JZBDnFDAnbZ-Mxi067A2dFmtQmSbFdefZgPl0li1Eho5_SAFUU3AYSSGTavWZKlTUi1e0JVNqz5ccTBjFoCcK82hSkMTSWNMsxo0PnezfJqdXMih3SC2FTt4kVJtEcW5cVypY-rkyjnXoCSGUMa4C_FYnrOz_SFledCzPMYmKwz4B66NFr0Y4apEdtTpxlndNF7wg_5DfxqGNFtmtS7MSHQTIMAeL5qBOHhcSSMqRYtTPuZznedQ9ef8fQu9GFaHnVshk8CdK2kwL-Bwk-6pIblUkwbSoSvMmKmL5Q3n0axLCnaVyXt78aNmMD8VIvlRnc5RhgKlhWjTr5O5Cl5cdiP6FN0OvTkRFy5cCyIVebUk_fSw40QOAvUHTvff3z9oma51xvxf1uoPj--Q6gN-iFojLtkhtdjHXDwBgzuKHdhZT8uGqDcdPFCKMZg |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGkYAXxMbHCoMZxMd4yNrETtwgoWlqV7Vs6-jYUN-C49gDUSVlaYXgT-Ov4y5xCkET8LK3Sr6kiX2--1189ztCnopQm1ByD9MqmAP41nVCz_ccN1Cs4BfXBaXQ4SgYnPI3E3-yQn5UtTCYVlnZxMJQJ5nCb-Qt8PzY4JKHomVsWsTbXn9n9sXBDlJ40lq10yhVZF9_-wrhW_562IO1fuZ5_b2T7sCxHQYcBUB-7vCwLU1bylAjJ4oQhoUJly4yNivFAIpInihfdSSXRig_4ALwT2xipo3hQZwwuO8VclUwzrFthJgsgz2wI0FgS_WYcFtWM7ZnWaq3wW8G8G81V2gdQmM2zfKL0O6fSZu_ecH-LXLTwle6W-rbKlnR6Rq5XlU352tk1RqLnG5ZRuuXt8n3Q4k0EGcU0CbdOzo-6dLxwdjpsjaVaVL8HjwfMZ_Os1Jk7Pg9CnCagqtICplUq89UoYqev6JdmVJ7suRgqSimO1HYQdOCHpbGmmYxfvLQyc4dcnopS3KXNFKY5HVCtUkU58Z1pYKgz5VxrENPCKGMcRUgtyZh1fxHyjKiY2OOaVQc8wmIjMpZjXDVIrtqTeIsr5qVjCD_kN_EpY3KutalQYl2A-SWg3A5aJInhQTScaSo2GdykefR8Oj9fwi9O64JvbBCJoM3UdLWWMDjIM1XTXKjJglGRdWG11ERqxfKo1_bD66slPPi4cfLYbwp5vClOlugDAM0Ddui0yT3Sl1eTiB6Ft4JvSYRNS1fCiALen0k_fSxYEMPAPAGHff-3x9rk1wDcxEdDEf7D8gNQL1FExCXbZDG_HyhHwKynMePii1MyYfLthk_AUQsigI |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mapping+the+EORTC+QLQ-C30+and+QLQ-H%26N35+to+the+EQ-5D+for+head+and+neck+cancer%3A+Can+disease-specific+utilities+be+obtained%3F&rft.jtitle=PloS+one&rft.au=Beck%2C+Ann-Jean+C.+C.&rft.au=Kieffer%2C+Jacobien+M.&rft.au=Ret%C3%A8l%2C+Valesca+P.&rft.au=van+Overveld%2C+Lydia+F.+J.&rft.date=2019-12-13&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=14&rft.issue=12&rft_id=info:doi/10.1371%2Fjournal.pone.0226077&rft_id=info%3Apmid%2F31834892&rft.externalDocID=PMC6910681 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |